Jim Simons’s Chemomab Therapeutics CMMB Stock Holding History

Jim Simons’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12.3K	Buy	+10,328	New	+$21.2K	﹤0.01%	3143
2022 Q2	–	Sell	-6,990	Closed	-$134K	–	4260
2022 Q1	$134K	Buy	+6,990	New	+$138K	﹤0.01%	3743
2021 Q2	–	Sell	-1,756	Closed	-$202K	–	3493
2021 Q1	$202K	Buy	1,756 +420	+31%	+$83.6K	﹤0.01%	3146
2020 Q4	$148K	Buy	+1,336	New	+$129K	﹤0.01%	3203

Other funds holding CMMB

Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Philadelphia Investment Partners Voorhees, New Jersey $163M AUM

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Jim Simons's CMMB Position: Q3 2026 in Review

Jim Simons opened a new position in Chemomab Therapeutics (CMMB) in Q3 2026: 10,328 shares worth $12.3K. The stake represents ﹤0.01% of the portfolio and ranks #3143 among its holdings. This is a return to the name: Jim Simons previously reported a position in CMMB as recently as Q1 2022.

Jim Simons first reported a position in CMMB in Q4 2020 and has held it in 4 quarters since. The position peaked at $202K in Q1 2021. 13 funds tracked by Wall St. Rank hold CMMB as of Q3 2026.

Jim Simons held 10,328 shares of Chemomab Therapeutics worth $12.3K as of Q3 2026.
Chemomab Therapeutics was a new Jim Simons position in Q3 2026.
Chemomab Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q3 2026, its #3143 holding.
Jim Simons first reported a position in Chemomab Therapeutics in Q4 2020 and has held it in 4 quarters since.
Jim Simons's Chemomab Therapeutics position peaked at $202K in Q1 2021.
13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.